Content provided in partnership with
Technology Industry
Industry: Email Alert RSS FeedViamet Pharmaceutical, a Research Triangle park biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, closed a $4 million Series A financing round
BT Catalyst, July-August, 2007
- Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »
> Viamet Pharmaceutical, a Research Triangle park biotechnology company targeting metalloenzymes in the fields of infectious disease, inflammation and oncology, closed a $4 million Series A financing round. The financing, to support the rapid development of Viamet's metalloenzyme inhibitor programs, was co-led by new investor Hatteras Venture Partners and founding investor Intersouth Partners, which previously provided seed funding for the company.
COPYRIGHT 2007 North Carolina Biotechnology Center
COPYRIGHT 2007 Gale Group
Find Research Guides for:
Find Featured Titles for: Reference
- Academe
- African American Review
- African Arts
- African Studies Review
- Afro-Americans in New York Life and History
- Alabama Heritage
- Alabama Review
- American Mathematical Monthly, The
- Anglican Theological Review
- Annals of Dyslexia
- Arab Studies Quarterly (ASQ)
- Auk, The
- Australian Journal of Anthropology, The
- Christian Century
- Natural History
Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »